[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Cell & Gene Therapy Manufacturing Services Market by Type (Allogeneic, Autologous, Viral Vector, Non-viral vector), Indication (Cancer, Orthopedic), Application (Clinical, Commercial), End User (Pharma & Biotech, Academia) - Global Forecast to 2026

July 2021 | 285 pages | ID: C18AEEC064AAEN
MarketsandMarkets

US$ 4,950.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
The global cell & gene therapy manufacturing services market size is projected to reach USD 13.8 billion by 2026 from USD 7.7billion in 2021, at a CAGR of 12.4% during the forecast period. Growth in this market is primarily driven by the high incidence of cancer and other target diseases, increasing investments in pharmaceutical R&D, investments in advanced technologies by CDMOs, and increasing partnerships & agreements between pharmaceutical companies and CDMOs. However, the high operational costs associated with cell & gene therapy manufacturing are expected to restrain the growth of this market to a certain extent.

“The clinical manufacturing segment accounted for the highest growth rate in thecell & gene therapy manufacturing servicesmarket, byapplication, during the forecast period”

The cell & gene therapy manufacturing services market is segmented into clinical manufacturing and commercial manufacturing on the basis of application. The clinical manufacturing segment accounted for the highest growth rate in the cell & gene therapy manufacturing servicesmarket during the forecast period. This segment's high growth rate can be attributed to increasing government funding for cancer research and the increasing number of cell & gene therapy clinical trials.

“Pharmaceutical & biotechnology companies segment accounted for the highest CAGR”

Based on end users, the cell & gene therapy manufacturing servicesmarket is segmented into pharmaceutical & biotechnology companies, academic & research institutes, and other end users. During the forecast periodpharmaceutical & biotechnology companies accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

“Cell Therapy segment accounted for the highest CAGR”

Based on type, the cell & gene therapy manufacturing servicesmarket is segmented intocell therapy and gene therapy. The cell therapy segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the increasing awareness about cell therapy, growing funding for new cell lines, increasing partnerships and acquisitions, and the development of advanced genomics methods for cell analysis.

“Infectious diseases segment accounted for the highest CAGR”

Based on indication, the cell & gene therapy manufacturing servicesmarket is segmented into oncology diseases, cardiovascular diseases, orthopedic diseases, ophthalmology diseases, infectious diseases, central nervous system disorders, and other indications. Theinfectious diseases segment accounted for the highest growth rate during the forecast period. The growth of this segment is attributed to the rising clinical trials for the development of cell therapies owing to the increasing prevalence of infectious diseases.

“Asia Pacific: The fastest-growing countryin thecell & gene therapy manufacturing servicesmarket”

TheCell & gene therapy manufacturing servicesmarket is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Increasing pharmaceutical R&D spending, the growing trend of outsourcing drug discovery services, growing life sciences research, and increasing government initiatives for healthcare research are the factors driving the growth of the cell & gene therapy manufacturing servicesmarket in this region.

The primary interviews conducted for this report can be categorized as follows:
  • By Respondent: Supply Side- 70%, and Demand Side -30%
  • By Designation (Supply Side): Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%
Lists of Companies Profiled in the Report:
  • Thermo Fisher Scientific, Inc. (US)
  • Merck KGaA (Germany)
  • Charles River Laboratories (US)
  • Lonza (Switzerland)
  • Catalent, Inc. (US)
  • WuXiAppTec (China)
  • Takara Bio Inc. (Japan)
  • NIKON CORPORATION (Japan)
  • FUJIFILM Holdings Corporation (Japan)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Oxford Biomedica plc (UK)
  • Cell and Gene Therapy Catapult (UK)
  • The Discovery Labs LLC (US)
  • RoslinCT (Scotland)
  • JRS PHARMA (Germany)
  • FinVector (Finland)
  • ABL, Inc. (US)
  • Resilience (US)
  • BioCentriq (US)
  • Porton Biopharma Limited (England)
  • Andelyn Biosciences (US)
  • Commercializing Living Therapies (Canada)
  • Vibalogics (US)
  • AnemocyteSrl (Italy)
  • ElevateBio (US)
Research Coverage:

This report provides a detailed picture of the cell & gene therapy manufacturing servicesmarket. It aims at estimating the size and future growth potential of the market across different segments, such as type, indication, application, end user, and region. The report also includes an in-depth competitive analysis ofthe key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall cell & gene therapy manufacturing servicesmarket and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
  1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
  1.3.1 MARKETS COVERED
  1.3.2 YEARS CONSIDERED IN THE REPORT
1.4 CURRENCY
1.5 LIMITATIONS
1.6 STAKEHOLDERS

2 RESEARCH METHODOLOGY

2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
  2.1.1 SECONDARY DATA
  2.1.2 PRIMARY DATA
FIGURE 2 PRIMARY SOURCES
FIGURE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: BREAKDOWN OF PRIMARIES
    2.1.2.1 Key industry insights
2.2 MARKET SIZE ESTIMATION
FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 –
REVENUE SHARE ANALYSIS, 2020
FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
FIGURE 6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: CAGR PROJECTIONS, 2021–2026
FIGURE 7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, AND OPPORTUNITIES
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 RESEARCH ASSUMPTIONS
2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

FIGURE 9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
FIGURE 10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 11 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
FIGURE 12 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET

4 PREMIUM INSIGHTS

4.1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET OVERVIEW
FIGURE 14 HIGH INCIDENCE OF CANCER AND OTHER TARGET DISEASES TO
DRIVE MARKET GROWTH
4.2 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE & COUNTRY (2020)
FIGURE 15 THE CELL THERAPY SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF
THE NORTH AMERICAN MARKET IN 2020
4.3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE, BY APPLICATION, 2020
FIGURE 16 THE CLINICAL MANUFACTURING SEGMENT DOMINATED THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET IN 2020
4.4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2021–2026
FIGURE 17 ASIA PACIFIC TO REGISTER THE HIGHEST GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 18 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
TABLE 1 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: IMPACT ANALYSIS
  5.2.1 DRIVERS
    5.2.1.1 High incidence of cancer and other target diseases
    5.2.1.2 Increasing investments in pharmaceutical R&D
FIGURE 19 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2016
    5.2.1.3 Investments in advanced technologies by CDMOs
    5.2.1.4 Increasing partnerships and agreements between pharmaceutical companies and CDMOs
  5.2.2 RESTRAINTS
    5.2.2.1 High operational costs associated with cell & gene therapy manufacturing
  5.2.3 OPPORTUNITIES
    5.2.3.1 Rising demand for cell & gene therapies
    5.2.3.2 Increasing number of cell & gene therapy clinical trials
  5.2.4 CHALLENGES
    5.2.4.1 Risk of mutagenesis and other unwanted outcomes
  5.2.5 TRENDS
    5.2.5.1 Expansion in emerging countries
5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
FIGURE 20 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SCENARIO, PRE-COVID-19 VS. POST-COVID-19 IMPACT, 2019–2021
5.4 TECHNOLOGICAL ANALYSIS
5.5 CASE STUDIES
  5.5.1 CGT CATAPULT PROVIDED ITS EXPERTISE IN THERAPIES DEVELOPMENT
AND MANUFACTURING TO CREATE A NEW PRECLINICAL DEVELOPMENT PLAN FOR PURESPRING THERAPEUTICS’ GENE THERAPY TECHNOLOGY FOR
KIDNEY DISEASES
5.6 RANGES/SCENARIO
FIGURE 21 SPECTRUM OF SCENARIOS BASED ON THE IMPACT OF UNCERTAINTIES
ON THE GROWTH OF THE CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET
5.7 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 22 REVENUE SHIFT & NEW POCKETS FOR CELL & GENE THERAPY MANUFACTURING SERVICE PROVIDERS
5.8 PRICING ANALYSIS
5.9 VALUE CHAIN ANALYSIS
FIGURE 23 VALUE CHAIN ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: HARVESTING AND CRYOPRESERVATION PHASES ADD MAXIMUM VALUE
5.10 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
FIGURE 24 ECOSYSTEM ANALYSIS OF THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET
TABLE 2 SUPPLY CHAIN ECOSYSTEM
5.11 PORTER’S FIVE FORCES ANALYSIS
TABLE 3 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: PORTER’S FIVE FORCES ANALYSIS
  5.11.1 THREAT FROM NEW ENTRANTS
  5.11.2 THREAT FROM SUBSTITUTES
  5.11.3 BARGAINING POWER OF BUYERS
  5.11.4 BARGAINING POWER OF SUPPLIERS
  5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 REGULATORY ANALYSIS
  5.12.1 NORTH AMERICA
    5.12.1.1 US
    5.12.1.2 Canada
  5.12.2 EUROPE
    5.12.2.1 Germany
    5.12.2.2 France
    5.12.2.3 UK
    5.12.2.4 Rest of Europe
  5.12.3 ASIA PACIFIC
    5.12.3.1 China
    5.12.3.2 Japan
    5.12.3.3 Rest of Asia Pacific
      5.12.3.3.1 India
      5.12.3.3.2 Australia and New Zealand
  5.12.4 LATIN AMERICA
  5.12.5 MIDDLE EAST & AFRICA
5.13 PATENT ANALYSIS
FIGURE 25 NUMBER OF PATENT APPLICATIONS FILED FOR CELL & GENE THERAPY MANUFACTURING SERVICES, JANUARY 2010–DECEMBER 2020

6 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE

6.1 INTRODUCTION
TABLE 4 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
6.2 CELL THERAPY
TABLE 5 CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 6 CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 7 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 8 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 9 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.2.1 ALLOGENEIC
TABLE 10 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 11 ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 12 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 13 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 14 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.1 Mesenchymal stem cells
      6.2.1.1.1 MSCs are ideal for cell therapy because of their immunosuppressive and tissue repair properties
TABLE 15 ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 16 NORTH AMERICA: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 17 EUROPE: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 18 ASIA PACIFIC: ALLOGENEIC MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.2 T-cells
      6.2.1.2.1 Allogeneic T-Cells are immediately available because of cryopreserved batches
TABLE 19 ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 20 NORTH AMERICA: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 21 EUROPE: ALLOGENEIC T-CELLS MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 22 ASIA PACIFIC: ALLOGENEIC T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.3 Induced pluripotent stem cells
      6.2.1.3.1 Growing adoption Of IPSCs in research to
drive market growth
TABLE 23 ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 24 NORTH AMERICA: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 25 EUROPE: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 26 ASIA PACIFIC: ALLOGENEIC INDUCED PLURIPOTENT STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.4 Natural killer cells
      6.2.1.4.1 Allogeneic natural killer cell therapies are used for advanced hepatocellular carcinoma patients
TABLE 27 ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 28 NORTH AMERICA: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 29 EUROPE: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 30 ASIA PACIFIC: ALLOGENEIC NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.5 Hematopoietic stem cells
      6.2.1.5.1 Stem cells from a donor are used for allogeneic transplantation
TABLE 31 ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 32 NORTH AMERICA: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 33 EUROPE: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 34 ASIA PACIFIC: ALLOGENEIC HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.1.6 Other allogeneic cells
TABLE 35 OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 36 NORTH AMERICA: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 37 EUROPE: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 38 ASIA PACIFIC: OTHER ALLOGENEIC CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.2.2 AUTOLOGOUS
TABLE 39 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 40 AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 41 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 42 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 43 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.2.1 T-cells
      6.2.2.1.1 T-cells are major components of the adaptive
immune system
TABLE 44 AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 45 NORTH AMERICA: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 46 EUROPE: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 47 ASIA PACIFIC: AUTOLOGOUS T-CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.2.2 Hematopoietic stem cells
      6.2.2.2.1 Hematopoietic stem cells are used to establish marrow
and bone function
TABLE 48 AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 49 NORTH AMERICA: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 50 EUROPE: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 51 ASIA PACIFIC: AUTOLOGOUS HEMATOPOIETIC STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.2.3 Mesenchymal stem cells
      6.2.2.3.1 Mesenchymal stem cells are present in the umbilical
cord, bone marrow, & fat tissue
TABLE 52 AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 53 NORTH AMERICA: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 54 EUROPE: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 55 ASIA PACIFIC: AUTOLOGOUS MESENCHYMAL STEM CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.2.4 Natural killer cells
      6.2.2.4.1 NK Cells are used in the treatment of tumors and
infectious diseases
TABLE 56 AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 57 NORTH AMERICA: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 58 EUROPE: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 59 ASIA PACIFIC: AUTOLOGOUS NATURAL KILLER CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.2.5 Other autologous cells
TABLE 60 OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 61 NORTH AMERICA: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 62 EUROPE: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 63 ASIA PACIFIC: OTHER AUTOLOGOUS CELL MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.2.3 VIRAL VECTOR
TABLE 64 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 65 VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 66 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 67 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 68 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.3.1 Retroviral vectors
      6.2.3.1.1 Retroviral vectors are the most used viral vectors for cell therapy manufacturing
TABLE 69 RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 70 NORTH AMERICA: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 71 EUROPE: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 72 ASIA PACIFIC: RETROVIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.3.2 Adeno-associated virus vectors
      6.2.3.2.1 AAV vector-based techniques are used for car-t cell
therapy development
TABLE 73 ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 74 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 75 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 76 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.2.3.3 Other viral vectors
TABLE 77 OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 78 NORTH AMERICA: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 79 EUROPE: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 80 ASIA PACIFIC: OTHER VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
6.3 GENE THERAPY
TABLE 81 GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 82 GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 83 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 84 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 85 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.3.1 NON-VIRAL VECTORS
TABLE 86 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 87 NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 88 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 89 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 90 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.1 Oligonucleotides
      6.3.1.1.1 North America accounted for the largest share of the oligonucleotides market
TABLE 91 OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 92 NORTH AMERICA: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 93 EUROPE: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 94 ASIA PACIFIC: OLIGONUCLEOTIDE MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.1.2 Other non-viral vectors
TABLE 95 OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 96 NORTH AMERICA: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 97 EUROPE: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 98 ASIA PACIFIC: OTHER NON-VIRAL VECTOR MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
  6.3.2 VIRAL VECTORS
TABLE 99 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 100 VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 101 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 102 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 103 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.2.1 Retroviral vectors
      6.3.2.1.1 Retroviral vectors possess the ability to replicate
within a cell
TABLE 104 RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 105 NORTH AMERICA: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 106 EUROPE: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 107 ASIA PACIFIC: RETROVIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.2.2 Adeno-associated virus vectors
      6.3.2.2.1 Adeno-associated virus vectors have low toxicity
TABLE 108 ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 109 NORTH AMERICA: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 110 EUROPE: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 111 ASIA PACIFIC: ADENO-ASSOCIATED VIRUS VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    6.3.2.3 Other viral vectors
TABLE 112 OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
TABLE 113 NORTH AMERICA: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 114 EUROPE: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 115 ASIA PACIFIC: OTHER VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

7 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION

7.1 INTRODUCTION
TABLE 116 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
7.2 ONCOLOGY DISEASES
  7.2.1 THE DEMAND FOR CELL & GENE THERAPIES IS INCREASING WITH THE RISING NUMBER OF CANCER CASES WORLDWIDE
TABLE 117 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 118 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 119 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 120 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ONCOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.3 CARDIOVASCULAR DISEASES
  7.3.1 GROWING INCIDENCE OF CARDIOVASCULAR DISEASES OWING TO SEDENTARY LIFESTYLES DRIVES THE MARKET GROWTH
TABLE 121 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 122 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 123 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 124 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CARDIOVASCULAR DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.4 ORTHOPEDIC DISEASES
  7.4.1 CELL THERAPY FOR ORTHOPEDIC DISEASES ELIMINATES
POST-TREATMENT COMPLICATIONS
TABLE 125 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 126 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 127 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 128 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ORTHOPEDIC DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.5 OPTHALMOLOGY DISEASES
  7.5.1 STEM CELL THERAPIES CAN BE USED FOR THE RESTORATION & PRESERVATION OF VISION; KEY FACTOR DRIVING MARKET GROWTH
TABLE 129 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 130 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 131 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 132 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OPTHALMOLOGY DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.6 CENTRAL NERVOUS SYSTEM DISORDERS
  7.6.1 INCREASING INCIDENCE OF SPINAL MUSCULAR ATROPHY SUPPORTS
THE MARKET GROWTH
TABLE 133 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 134 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 135 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 136 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CENTRAL NERVOUS SYSTEM DISORDERS, BY COUNTRY, 2019–2026 (USD MILLION)
7.7 INFECTIOUS DISEASES
  7.7.1 THE INCREASING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE
THE MARKET GROWTH OF THIS SEGMENT
TABLE 137 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY REGION, 2019–2026 (USD MILLION)
TABLE 138 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 139 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 140 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR INFECTIOUS DISEASES, BY COUNTRY, 2019–2026 (USD MILLION)
7.8 OTHER INDICATIONS
TABLE 141 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY REGION, 2019–2026 (USD MILLION)
TABLE 142 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 143 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 144 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

8 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION

8.1 INTRODUCTION
TABLE 145 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
8.2 CLINICAL MANUFACTURING
  8.2.1 THE RISING NUMBER OF CLINICAL TRIALS FOR CELL & GENE THERAPIES IS EXPECTED TO DRIVE THE GROWTH OF THIS SEGMENT
TABLE 146 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)
TABLE 147 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 148 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 149 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR CLINICAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
8.3 COMMERCIAL MANUFACTURING
  8.3.1 MARKET GROWTH CAN BE ATTRIBUTED TO THE INCREASING APPROVALS OF CELL & GENE THERAPY PRODUCTS FOR COMMERCIAL MANUFACTURING
TABLE 150 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY REGION, 2019–2026 (USD MILLION)
TABLE 151 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 152 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 153 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR COMMERCIAL MANUFACTURING, BY COUNTRY, 2019–2026 (USD MILLION)

9 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER

9.1 INTRODUCTION
TABLE 154 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  9.2.1 GROWING NUMBER OF CELL & GENE THERAPIES IN THE R&D PIPELINE TO DRIVE THE MARKET GROWTH
TABLE 155 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019–2026 (USD MILLION)
TABLE 156 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 157 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 158 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019–2026 (USD MILLION)
9.3 ACADEMIC & RESEARCH INSTITUTES
  9.3.1 INCREASE IN LIFE SCIENCES R&D EXPENDITURE TO CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
TABLE 159 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2019–2026 (USD MILLION)
TABLE 160 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 161 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 162 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
9.4 OTHER END USERS
TABLE 163 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY REGION, 2019–2026 (USD MILLION)
TABLE 164 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 165 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 166 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

10 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY REGION

10.1 INTRODUCTION
TABLE 167 CELL & GENE THERAPY MANUFACTURING THERAPY SERVICES MARKET, BY REGION, 2019–2026 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 26 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SNAPSHOT
TABLE 168 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 169 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 170 NORTH AMERICA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 171 NORTH AMERICA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 172 NORTH AMERICA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 173 NORTH AMERICA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 174 NORTH AMERICA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 175 NORTH AMERICA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 176 NORTH AMERICA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 177 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 178 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 179 NORTH AMERICA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.2.1 US
    10.2.1.1 Growing focus on cancer research in the US will drive market growth
TABLE 180 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 181 US: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 182 US: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 183 US: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 184 US: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 185 US: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 186 US: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 187 US: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 188 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 189 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 190 US: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.2.2 CANADA
    10.2.2.1 Growth in Canada can be attributed to the rising funding for stem cell research in the country
TABLE 191 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 192 CANADA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 193 CANADA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 194 CANADA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 195 CANADA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 196 CANADA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 197 CANADA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 198 CANADA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 199 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 200 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 201 CANADA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.3 EUROPE
TABLE 202 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 203 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 204 EUROPE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 205 EUROPE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 206 EUROPE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 207 EUROPE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 208 EUROPE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 209 EUROPE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 210 EUROPE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 211 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 212 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 213 EUROPE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.3.1 GERMANY
    10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
TABLE 214 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 215 GERMANY: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 216 GERMANY: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 217 GERMANY: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 218 GERMANY: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 219 GERMANY: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 220 GERMANY: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 221 GERMANY: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 222 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 223 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 224 GERMANY: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.3.2 UK
    10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
TABLE 225 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 226 UK: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 227 UK: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 228 UK: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 229 UK: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 230 UK: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 231 UK: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 232 UK: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 233 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 234 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 235 UK: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.3.3 FRANCE
    10.3.3.1 Growth can be attributed to rising government funding for
cancer research
TABLE 236 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 237 FRANCE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 238 FRANCE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 239 FRANCE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 240 FRANCE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 241 FRANCE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 242 FRANCE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 243 FRANCE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 244 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 245 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 246 FRANCE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.3.4 REST OF EUROPE
TABLE 247 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 248 ROE: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 249 ROE: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 250 ROE: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 251 ROE: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 252 ROE: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 253 ROE: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 254 ROE: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 255 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 256 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 257 ROE: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 27 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING
SERVICES MARKET SNAPSHOT
TABLE 258 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
TABLE 259 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 260 ASIA PACIFIC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 261 ASIA PACIFIC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 262 ASIA PACIFIC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 263 ASIA PACIFIC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 264 ASIA PACIFIC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 265 ASIA PACIFIC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 266 ASIA PACIFIC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 267 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 268 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 269 ASIA PACIFIC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.4.1 CHINA
    10.4.1.1 The growing pharmaceutical industry and rising number of CDMOs in the country will drive market growth
TABLE 270 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 271 CHINA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 272 CHINA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 273 CHINA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 274 CHINA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 275 CHINA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 276 CHINA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 277 CHINA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 278 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 279 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 280 CHINA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.4.2 JAPAN
    10.4.2.1 Research collaborations and growing geriatric population—
key growth drivers in Japan
TABLE 281 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 282 JAPAN: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 283 JAPAN: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 284 JAPAN: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 285 JAPAN: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 286 JAPAN: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 287 JAPAN: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 288 JAPAN: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 289 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 290 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 291 JAPAN: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
  10.4.3 REST OF ASIA PACIFIC
TABLE 292 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 293 ROAPAC: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 294 ROAPAC: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 295 ROAPAC: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 296 ROAPAC: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 297 ROAPAC: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 298 ROAPAC: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 299 ROAPAC: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 300 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 301 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 302 ROAPAC: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.5 LATIN AMERICA
  10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
TABLE 303 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 304 LATAM: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 305 LATAM: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 306 LATAM: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 307 LATAM: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 308 LATAM: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 309 LATAM: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 310 LATAM: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 311 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 312 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 313 LATAM: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
  10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
TABLE 314 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 315 MEA: CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 316 MEA: ALLOGENEIC CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 317 MEA: AUTOLOGOUS CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 318 MEA: VIRAL VECTOR CELL THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 319 MEA: GENE THERAPY MANUFACTURING SERVICES MARKET, BY VECTOR, 2019–2026 (USD MILLION)
TABLE 320 MEA: NON-VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 321 MEA: VIRAL VECTOR GENE THERAPY MANUFACTURING SERVICES MARKET, BY TYPE, 2019–2026 (USD MILLION)
TABLE 322 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY INDICATION, 2019–2026 (USD MILLION)
TABLE 323 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
TABLE 324 MEA: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, BY END USER, 2019–2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
FIGURE 28 KEY PLAYER STRATEGIES IN THE CELL & GENE THERAPY MANUFACTURING SERVICES MARKET, 2018–2021
11.3 MARKET SHARE ANALYSIS
FIGURE 29 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
FIGURE 30 REVENUE SHARE ANALYSIS OF KEY MARKET PLAYERS
11.5 COMPANY EVALUATION QUADRANT
  11.5.1 STARS
  11.5.2 EMERGING LEADERS
  11.5.3 PERVASIVE PLAYERS
  11.5.4 EMERGING COMPANIES
FIGURE 31 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT, 2020
11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
  11.6.1 PROGRESSIVE COMPANIES
  11.6.2 STARTING BLOCKS
  11.6.3 RESPONSIVE COMPANIES
  11.6.4 DYNAMIC COMPANIES
FIGURE 32 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
11.7 SERVICE FOOTPRINT OF COMPANIES
TABLE 325 SERVICE PORTFOLIO ANALYSIS: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)
11.8 REGIONAL FOOTPRINT OF COMPANIES
TABLE 326 REGIONAL FOOTPRINT OF COMPANIES: CELL & GENE THERAPY MANUFACTURING SERVICES MARKET (2020)
11.9 COMPETITIVE SCENARIO
TABLE 327 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: DEALS, JANUARY 2018–JUNE 2021
TABLE 328 CELL & GENE THERAPY MANUFACTURING SERVICES MARKET: OTHER DEVELOPMENTS, JANUARY 2018 –JUNE 2021

12 COMPANY PROFILES

12.1 KEY MARKET PLAYERS
(Business Overview, Services Offered, Recent Developments, and MnM View)*
  12.1.1 THERMO FISHER SCIENTIFIC, INC.
TABLE 329 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
FIGURE 33 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2020)
  12.1.2 MERCK KGAA
TABLE 330 MERCK KGAA: BUSINESS OVERVIEW
FIGURE 34 MERCK KGAA: COMPANY SNAPSHOT (2020)
  12.1.3 CHARLES RIVER LABORATORIES
TABLE 331 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
FIGURE 35 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
  12.1.4 LONZA
TABLE 332 LONZA: BUSINESS OVERVIEW
FIGURE 36 LONZA: COMPANY SNAPSHOT (2020)
  12.1.5 CATALENT, INC.
TABLE 333 CATALENT, INC.: BUSINESS OVERVIEW
FIGURE 37 CATALENT, INC.: COMPANY SNAPSHOT (2020)
  12.1.6 TAKARA BIO INC.
TABLE 334 TAKARA BIO INC.: BUSINESS OVERVIEW
FIGURE 38 TAKARA BIO INC.: COMPANY SNAPSHOT (2020)
  12.1.7 OXFORD BIOMEDICA PLC
TABLE 335 OXFORD BIOMEDICA PLC: BUSINESS OVERVIEW
FIGURE 39 OXFORD BIOMEDICA PLC: COMPANY SNAPSHOT (2020)
  12.1.8 CELL AND GENE THERAPY CATAPULT
TABLE 336 CELL AND GENE THERAPY CATAPULT: BUSINESS OVERVIEW
FIGURE 40 CELL AND GENE THERAPY CATAPULT: COMPANY SNAPSHOT (2020)
  12.1.9 F. HOFFMANN-LA ROCHE LTD.
TABLE 337 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW
FIGURE 41 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2020)
  12.1.10 FUJIFILM HOLDINGS CORPORATION
TABLE 338 FUJIFILM HOLDINGS CORPORATION: BUSINESS OVERVIEW
FIGURE 42 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2020)
  12.1.11 WUXI APPTEC
TABLE 339 WUXI APPTEC: BUSINESS OVERVIEW
FIGURE 43 WUXI APPTEC: COMPANY SNAPSHOT (2020)
  12.1.12 NIKON CORPORATION
TABLE 340 NIKON CORPORATION: BUSINESS OVERVIEW
FIGURE 44 NIKON CORPORATION: COMPANY SNAPSHOT (2020)
12.2 OTHER PLAYERS
  12.2.1 THE DISCOVERY LABS LLC
TABLE 341 THE DISCOVERY LABS LLC: BUSINESS OVERVIEW
  12.2.2 ROSLINCT
TABLE 342 ROSLINCT: BUSINESS OVERVIEW
  12.2.3 JRS PHARMA
TABLE 343 JRS PHARMA: BUSINESS OVERVIEW
  12.2.4 FINVECTOR
TABLE 344 FINVECTOR: BUSINESS OVERVIEW
  12.2.5 ABL, INC.
TABLE 345 ABL, INC.: BUSINESS OVERVIEW
  12.2.6 RESILIENCE, INC.
TABLE 346 RESILIENCE, INC.: BUSINESS OVERVIEW
  12.2.7 BIOCENTRIQ
TABLE 347 BIOCENTRIQ: BUSINESS OVERVIEW
  12.2.8 PORTON BIOPHARMA LIMITED
TABLE 348 PORTON BIOPHARMA LIMITED: BUSINESS OVERVIEW
  12.2.9 ANDELYN BIOSCIENCES
  12.2.10 COMMERCIALIZING LIVING THERAPIES
  12.2.11 VIBALOGICS
  12.2.12 ANEMOCYTE SRL
  12.2.13 ELEVATE BIO
* Business Overview, Services Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.

13 APPENDIX

13.1 DISCUSSION GUIDE
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 AVAILABLE CUSTOMIZATIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS


More Publications